Test Price
1,800 AED✅ Home Collection Available
MGMT Promoter Methylation Test in Dubai, UAE | 1,800 AED | DHA Licensed
Executive Summary & Core Metrics
- ✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO Accredited Processing.
- ✓ Sample Collection: Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
- ✓ Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation.
- ✓ Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The MGMT promoter methylation test identifies epigenetic silencing of the O6‑methylguanine DNA methyltransferase repair enzyme, a decisive biomarker for predicting response to alkylating agents such as temozolomide in glioblastoma and other malignancies. Methylation of the MGMT promoter reduces DNA repair capacity, rendering tumor cells more susceptible to chemotherapy. This test is essential for guiding oncologic treatment decisions and clinical trial eligibility.
| Feature | Our Test (MGMT Methylation) | Closest Alternative |
|---|---|---|
| Methodology | Methylation‑Specific PCR (MS‑PCR) – gold standard | Pyrosequencing (limited availability, higher cost) |
| Precision | High sensitivity for low methylation signal | Lower sensitivity in heterogeneous samples |
| Turnaround | 13 working days (Monday receipt) | 14–21 days |
Physician Insight & Safety Protocols
Mr. Prabhakar Reddy Kalathoor (Specialist Diagnostic Radiology, DHA Registration ID: 61713011): "Each MGMT result reveals a critical treatment opportunity. I personally correlate methylation status with tumor histology and clinical history to ensure no patient misses a chance for effective alkylating therapy. Share this report with your oncologist immediately for integrated treatment planning."
⚠️ Critical Advisory
Do not discontinue or alter prescribed chemotherapy without consulting your treating oncologist. This test is a predictive biomarker and must be interpreted within the full clinical context—it is not a standalone therapeutic directive.
Exclusion Criteria & Sample Rejection
- Tissue sample that is frozen, damaged, or not placed in sterile normal saline will be rejected.
- Incomplete Genomics Clinical Information Requisition Form (Form 20) will delay processing.
- Biopsy obtained from non‑lesional or necrotic tissue is unsuitable for analysis.
Emergency Red Flags:
If you experience severe headache, new neurological deficits, or seizures after the biopsy procedure, seek immediate emergency medical care.
Patient FAQ & Clinical Guidance
1. What is the MGMT methylation test used for?
This genomic assay determines whether the MGMT gene in your tumor is epigenetically silenced, predicting the effectiveness of temozolomide and other alkylating agents with high accuracy. The result directly guides your oncologist in selecting chemotherapy and may influence clinical trial eligibility.
Methylation of the MGMT promoter indicates reduced DNA repair capacity, which correlates with better treatment response and improved survival outcomes in glioblastoma.
2. How should I prepare for the MGMT test?
Submit a fresh biopsy specimen in sterile normal saline, refrigerated and never frozen. The completed Genomics Requisition Form 20 must accompany the sample. Our clinical team will provide the appropriate sterile container and coordinate cold‑chain transport to the ISO‑accredited laboratory.
Proper specimen handling is critical for accurate methylation analysis. Any deviation from these requirements may result in sample rejection or delayed results.
3. How long do results take and how will I receive them?
MGMT methylation status by MS‑PCR is reported within 13 working days from sample receipt on a Monday. You will receive a secure electronic report, and our clinical team offers a tele‑guidance session to explain the findings and their implications for your treatment plan.
Rush processing is not available for this test due to the rigorous quality controls required for methylation analysis.
UAE Regulatory & Data Privacy Adherence
All clinical data and genetic information are processed in full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent and clinical safety follow the standards set by Federal Decree-Law No. 4 of 2016 on Medical Liability. Your genomic data remains confidential and is used solely for diagnostic purposes.
Clinical & Logistical Metadata
| Test Name | MGMT Promoter Methylation Test |
| Price (AED) | 1,800 AED |
| Turnaround Time | 13 working days (Monday sample receipt) |
| Sample Type / Matrix | Fresh biopsy tissue in sterile normal saline (Hospital Extraction Only) |
| Methodology Used | Methylation‑Specific PCR (MS‑PCR) |
| ICD-10-CM Code | C71.9 |
| LOINC Code | 94220-7 |
| DHA Facility License & Laboratory Address | DHA License: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians